Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) Net Income towards Common Stockholders (2021 - 2025)

Historic Net Income towards Common Stockholders for HCW Biologics (HCWB) over the last 5 years, with Q3 2025 value amounting to -$4.6 million.

  • HCW Biologics' Net Income towards Common Stockholders fell 1670.94% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.3 million, marking a year-over-year increase of 4053.52%. This contributed to the annual value of -$30.1 million for FY2024, which is 1580.99% down from last year.
  • Per HCW Biologics' latest filing, its Net Income towards Common Stockholders stood at -$4.6 million for Q3 2025, which was down 1670.94% from -$12.1 million recorded in Q2 2025.
  • HCW Biologics' Net Income towards Common Stockholders' 5-year high stood at -$2.1 million during Q1 2022, with a 5-year trough of -$15.3 million in Q2 2024.
  • Its 5-year average for Net Income towards Common Stockholders is -$5.5 million, with a median of -$4.1 million in 2021.
  • Per our database at Business Quant, HCW Biologics' Net Income towards Common Stockholders plummeted by 23174.28% in 2024 and then surged by 7035.33% in 2025.
  • Quarter analysis of 5 years shows HCW Biologics' Net Income towards Common Stockholders stood at -$3.1 million in 2021, then tumbled by 85.12% to -$5.8 million in 2022, then crashed by 86.87% to -$10.8 million in 2023, then soared by 68.35% to -$3.4 million in 2024, then plummeted by 33.64% to -$4.6 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$4.6 million for Q3 2025, versus -$12.1 million for Q2 2025 and -$2.2 million for Q1 2025.